Cargando…
Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera
A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877760/ https://www.ncbi.nlm.nih.gov/pubmed/35215927 http://dx.doi.org/10.3390/v14020335 |
_version_ | 1784658495786713088 |
---|---|
author | Zhou, Wenhao He, Ping Li, Junhua Liu, Huan Shi, Mengjuan Yu, Junping Wei, Hongping |
author_facet | Zhou, Wenhao He, Ping Li, Junhua Liu, Huan Shi, Mengjuan Yu, Junping Wei, Hongping |
author_sort | Zhou, Wenhao |
collection | PubMed |
description | A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant. |
format | Online Article Text |
id | pubmed-8877760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88777602022-02-26 Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera Zhou, Wenhao He, Ping Li, Junhua Liu, Huan Shi, Mengjuan Yu, Junping Wei, Hongping Viruses Communication A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant. MDPI 2022-02-07 /pmc/articles/PMC8877760/ /pubmed/35215927 http://dx.doi.org/10.3390/v14020335 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Zhou, Wenhao He, Ping Li, Junhua Liu, Huan Shi, Mengjuan Yu, Junping Wei, Hongping Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title_full | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title_fullStr | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title_full_unstemmed | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title_short | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
title_sort | steep decline in binding capability of sars-cov-2 omicron variant (b.1.1.529) rbd to the antibodies in early covid-19 convalescent sera and inactivated vaccine sera |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877760/ https://www.ncbi.nlm.nih.gov/pubmed/35215927 http://dx.doi.org/10.3390/v14020335 |
work_keys_str_mv | AT zhouwenhao steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT heping steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT lijunhua steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT liuhuan steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT shimengjuan steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT yujunping steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT weihongping steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera |